Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

被引:527
作者
Cho, Jang Hwan [1 ,2 ]
Collins, James J. [3 ,4 ,5 ,6 ,7 ,8 ]
Wong, Wilson W. [1 ,2 ]
机构
[1] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA
[2] Boston Univ, Biol Design Ctr, Boston, MA 02215 USA
[3] MIT, Synthet Biol Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[4] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[5] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[6] Harvard MIT Program Hlth Sci & Technol, Cambridge, MA 02139 USA
[7] Broad Inst MIT & Harvard, 415 Main St, Cambridge, MA 02142 USA
[8] Harvard Univ, Wyss Inst Biol Inspired Engn, 3 Blackfan Circle, Boston, MA 02115 USA
基金
美国国家科学基金会; 英国生物技术与生命科学研究理事会;
关键词
B-CELL; OVARIAN-CANCER; FUSION PROTEINS; TARGET-CELLS; HALF-LIFE; IN-VITRO; CAR; INTRAPERITONEAL; STIMULATION; RECOGNITION;
D O I
10.1016/j.cell.2018.03.038
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the capability of CAR T cells, here, we present a split, universal, and programmable (SUPRA) CAR system that simultaneously encompasses multiple critical "upgrades," such as the ability to switch targets without re-engineering the T cells, finely tune T cell activation strength, and sense and logically respond to multiple antigens. These features are useful to combat relapse, mitigate over-activation, and enhance specificity. We test our SUPRA system against two different tumor models to demonstrate its broad utility and humanize its components to minimize potential immunogenicity concerns. Furthermore, we extend the orthogonal SUPRA CAR system to regulate different T cell subsets independently, demonstrating a dually inducible CAR system. Together, these SUPRA CARs illustrate that multiple advanced logic and control features can be implemented into a single, integrated system.
引用
收藏
页码:1426 / +
页数:24
相关论文
共 65 条
[1]   Toxicity and management in CAR T-cell therapy [J].
Bonifant, Challice L. ;
Jackson, Hollie J. ;
Brentjens, Renier J. ;
Curran, Kevin J. .
MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16011
[2]   CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].
Brentjens, Renier J. ;
Davila, Marco L. ;
Riviere, Isabelle ;
Park, Jae ;
Wang, Xiuyan ;
Cowell, Lindsay G. ;
Bartido, Shirley ;
Stefanski, Jolanta ;
Taylor, Clare ;
Olszewska, Malgorzata ;
Borquez-Ojeda, Oriana ;
Qu, Jinrong ;
Wasielewska, Teresa ;
He, Qing ;
Bernal, Yvette ;
Rijo, Ivelise V. ;
Hedvat, Cyrus ;
Kobos, Rachel ;
Curran, Kevin ;
Steinherz, Peter ;
Jurcic, Joseph ;
Rosenblat, Todd ;
Maslak, Peter ;
Frattini, Mark ;
Sadelain, Michel .
SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)
[3]   Toxicities of chimeric antigen receptor T cells: recognition and management [J].
Brudno, Jennifer N. ;
Kochenderfer, James N. .
BLOOD, 2016, 127 (26) :3321-3330
[4]   Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts [J].
Cartellieri, M. ;
Feldmann, A. ;
Koristka, S. ;
Arndt, C. ;
Loff, S. ;
Ehninger, A. ;
von Bonin, M. ;
Bejestani, E. P. ;
Ehninger, G. ;
Bachmann, M. P. .
BLOOD CANCER JOURNAL, 2016, 6 :e458-e458
[5]   Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[6]   Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity [J].
Caruso, Hillary G. ;
Hurton, Lenka V. ;
Najjar, Amer ;
Rushworth, David ;
Ang, Sonny ;
Olivares, Simon ;
Mi, Tiejuan ;
Switzer, Kirsten ;
Singh, Harjeet ;
Huls, Helen ;
Lee, Dean A. ;
Heimberger, Amy B. ;
Champlin, Richard E. ;
Cooper, Laurence J. N. .
CANCER RESEARCH, 2015, 75 (17) :3505-3518
[7]   Molecular mechanisms of T cell co-stimulation and co-inhibition [J].
Chen, Lieping ;
Flies, Dallas B. .
NATURE REVIEWS IMMUNOLOGY, 2013, 13 (04) :227-242
[8]   T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity [J].
Chmielewski, M ;
Hombach, A ;
Heuser, C ;
Adams, GP ;
Abken, H .
JOURNAL OF IMMUNOLOGY, 2004, 173 (12) :7647-7653
[9]   Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].
Davila, Marco L. ;
Riviere, Isabelle ;
Wang, Xiuyan ;
Bartido, Shirley ;
Park, Jae ;
Curran, Kevin ;
Chung, Stephen S. ;
Stefanski, Jolanta ;
Borquez-Ojeda, Oriana ;
Olszewska, Malgorzata ;
Qu, Jinrong ;
Wasielewska, Teresa ;
He, Qing ;
Fink, Mitsu ;
Shinglot, Himaly ;
Youssif, Maher ;
Satter, Mark ;
Wang, Yongzeng ;
Hosey, James ;
Quintanilla, Hilda ;
Halton, Elizabeth ;
Bernal, Yvette ;
Bouhassira, Diana C. G. ;
Arcila, Maria E. ;
Gonen, Mithat ;
Roboz, Gail J. ;
Maslak, Peter ;
Douer, Dan ;
Frattini, Mark G. ;
Giralt, Sergio ;
Sadelain, Michel ;
Brentjens, Renier .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
[10]   Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy [J].
Di Stasi, Antonio ;
Tey, Siok-Keen ;
Dotti, Gianpietro ;
Fujita, Yuriko ;
Kennedy-Nasser, Alana ;
Martinez, Caridad ;
Straathof, Karin ;
Liu, Enli ;
Durett, April G. ;
Grilley, Bambi ;
Liu, Hao ;
Cruz, Conrad R. ;
Savoldo, Barbara ;
Gee, Adrian P. ;
Schindler, John ;
Krance, Robert A. ;
Heslop, Helen E. ;
Spencer, David M. ;
Rooney, Cliona M. ;
Brenner, Malcolm K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) :1673-1683